Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. director Steven W. Lefkowitz reported exercising stock options for 15,000 shares of common stock on January 12, 2026. The options had an exercise price of $5.63 per share, and he paid the exercise price in cash. The filing states that no sales of stock were made in connection with this transaction.
After the option exercise, Lefkowitz directly beneficially owns 95,498 shares of CorMedix common stock. He also indirectly beneficially owns 30,152 shares through the Wade Capital Corporation Money Purchase Plan, an entity for which he has voting and investment control, and an additional 2,000 shares are held indirectly through his wife. The exercised option covering 15,000 shares was fully vested and now shows a remaining balance of zero.
CorMedix Inc. filed a current report describing preliminary results and leadership changes. The company issued a press release with preliminary financial results for the quarter and year ended December 31, 2025, noting that the figures are preliminary and subject to completion of audit and accounting procedures.
The report also details an amended and restated employment agreement with CEO Joseph Todisco. His annual base salary increased from $665,000 to $750,000 effective January 1, 2026, and his target annual bonus rose from 65% to 75% of base salary beginning with the 2026 fiscal year. He will continue as Chief Executive Officer and, effective January 8, 2026, will also serve as Chairman of the board of directors. The agreement provides severance protections, including up to 18 months of salary continuation, enhanced benefits and equity acceleration if certain termination or change-in-control conditions occur, and includes confidentiality, non-disparagement, non-compete and non-solicitation covenants.
CorMedix Inc. filed a current report describing preliminary results and leadership changes. The company issued a press release with preliminary financial results for the quarter and year ended December 31, 2025, noting that the figures are preliminary and subject to completion of audit and accounting procedures.
The report also details an amended and restated employment agreement with CEO Joseph Todisco. His annual base salary increased from $665,000 to $750,000 effective January 1, 2026, and his target annual bonus rose from 65% to 75% of base salary beginning with the 2026 fiscal year. He will continue as Chief Executive Officer and, effective January 8, 2026, will also serve as Chairman of the board of directors. The agreement provides severance protections, including up to 18 months of salary continuation, enhanced benefits and equity acceleration if certain termination or change-in-control conditions occur, and includes confidentiality, non-disparagement, non-compete and non-solicitation covenants.
CorMedix Inc.'s Chief Legal Officer reported an insider share transaction. A Form 4 filing shows a transaction in CorMedix Inc. common stock on January 2, 2026, coded "F". The transaction involved 11,333 shares at a price of $12.16 per share. Following this activity, the reporting person directly beneficially owns 169,085 shares of CorMedix common stock.
CorMedix Inc. director Janet Dillione reported exercising stock options and selling shares of the company’s common stock on 12/09/2025. She exercised options to buy 19,000 shares at $9.55 per share and another 15,000 shares at $5.63 per share, receiving a total of 34,000 shares.
On the same day, she sold 34,000 shares of CorMedix common stock at a weighted average price of $12.00 per share, with individual trades ranging from $12.00 to $12.02. After these transactions, she directly owned 48,473 shares of CorMedix common stock. The exercised options, originally granted in 2016 and 2020 and now fully vested, were reduced to zero following the transactions.
CorMedix Inc. director Steven Lefkowitz reported an open-market sale of common stock. On 12/09/2025, he sold 40,000 shares of CorMedix common stock at a weighted average price of $11.88 per share, with individual trades executed between $11.87 and $11.92. After this transaction, he directly owned 80,498 shares of CorMedix common stock.
In addition to his direct holdings, Lefkowitz is reported to beneficially own 30,152 shares through the Wade Capital Corporation Money Purchase Plan, for which he has voting and investment control, and 2,000 shares held by his wife. The filing reflects a routine insider ownership update rather than a company-level financing or operational event.
CorMedix Inc. (CRMD) director reports stock sale. A company director filed a Form 4 disclosing the sale of 30,000 shares of CorMedix common stock on 11/14/2025 at a weighted average price of $11.42 per share. The trades were executed in multiple transactions at prices ranging from $11.41 to $11.44. After this sale, the director beneficially owns 48,473 shares of CorMedix common stock in direct ownership.
CorMedix Inc. filed a Form S-8 registering 7,672,000 shares of common stock for issuance under its Amended and Restated 2019 Omnibus Stock Incentive Plan.
The increase reflects plan amendments approved by the Board on September 17, 2024 and October 7, 2024 and by stockholders on November 21, 2024, and a second amendment approved by the Board on September 14, 2025 and by stockholders on November 10, 2025. The filing incorporates prior S-8 registrations by reference.
CorMedix Inc. (CRMD) reported a profitable quarter and closed a transformative acquisition. Q3 2025 revenue was $104.3 million, driven by $101.5 million in product sales and $2.7 million in contract revenue. Gross profit reached $93.1 million and income from operations was $51.3 million. A tax benefit of $56.0 million contributed to net income of $108.6 million (basic EPS $1.42; diluted $1.26).
On August 29, 2025, CorMedix acquired Melinta, adding six marketed anti-infectives plus TOPROL‑XL and recording $390.0 million of intangible assets and $17.5 million of goodwill. Year‑to‑date, revenue was $183.1 million with net income of $149.0 million and operating cash flow of $80.6 million. To help fund the deal, the company issued $150.0 million 4.00% Convertible Senior Notes due 2030 and recognized $95.9 million of contingent consideration at fair value. Cash and cash equivalents were $48.5 million, stockholders’ equity was $374.1 million, and total assets were $750.9 million. Shares outstanding were 78,789,045 as of November 10, 2025.
CorMedix Inc. (CRMD) furnished an update on its business by announcing financial results for the quarter ended September 30, 2025. The company disclosed the results through a press release attached as Exhibit 99.1.
The information was provided under Item 2.02 and is being treated as “furnished,” not “filed,” which means it is not subject to Section 18 of the Exchange Act nor incorporated by reference unless specifically stated.
CorMedix Inc. (CRMD) director reported an open‑market purchase of 25,000 shares of common stock on 10/23/2025 at a weighted average price of $11.02 (transactions ranged from $11.01 to $11.03), coded “P” for purchase.
Following the transaction, the reporting person beneficially owns 201,034 shares directly. The filing also lists 20,000 shares held indirectly by a spouse and 10,000 shares held indirectly as spouse acting as guardian for grandchildren; beneficial ownership of these indirect holdings is disclaimed.